OBJECTIVES: XRCC2 and XRCC3 are key components of the homologous recombination (HR) machinery that repairs DNA double-strand breaks. We hypothesized that the altered HR repair capacity conferred by single nucleotide polymorphisms (SNPs) would modify individual susceptibility to sporadic pancreatic cancer. METHODS: In a hospital-based case-control study, genomic DNA and exposure information was obtained from 468 patients with pathologically confirmed pancreatic adenocarcinoma and 498 frequency-matched healthy controls at M.D. Anderson Cancer Center during January 2000 to September 2006. Genotypes of XRCC2 31479 G>A (Arg188His) and XRCC3 17893 A>G and 18067 C>T (Thr241Met) were determined using the Masscode technology. Unconditional logistic regression models were used to estimate the odds ratio (OR) and its 95% confidence interval (CI) in non-Hispanic whites (408 cases and 449 controls). RESULTS: The distribution of genotype frequencies was not different between cases and controls. We observed a significant effect modification between XRCC2 polymorphism and smoking status and pack-year of smoking in modifying pancreatic cancer risk (P value for interaction 0.02 and 0.05, respectively). Compared with never-smokers carrying the XRCC2 Arg188Arg genotype, the OR (95% CI) for individuals carrying the (188)His allele was 2.32 (1.25-4.31) among ever-smokers, 1.43 (0.59-3.48) among light smokers (< or = 22 pack-years), and 3.42 (1.47-7.96) among heavy smokers (> or =22 pack-years). The two XRCC3 SNPs are in strong linkage disequilibrium, but there was no suggestive association between XRCC3 genotype and the risk of pancreatic cancer. CONCLUSION: XRCC2 Arg188His polymorphism may be one of the genetic modifiers for smoking-related pancreatic cancer.
OBJECTIVES:XRCC2 and XRCC3 are key components of the homologous recombination (HR) machinery that repairs DNA double-strand breaks. We hypothesized that the altered HR repair capacity conferred by single nucleotide polymorphisms (SNPs) would modify individual susceptibility to sporadic pancreatic cancer. METHODS: In a hospital-based case-control study, genomic DNA and exposure information was obtained from 468 patients with pathologically confirmed pancreatic adenocarcinoma and 498 frequency-matched healthy controls at M.D. Anderson Cancer Center during January 2000 to September 2006. Genotypes of XRCC2 31479 G>A (Arg188His) and XRCC3 17893 A>G and 18067 C>T (Thr241Met) were determined using the Masscode technology. Unconditional logistic regression models were used to estimate the odds ratio (OR) and its 95% confidence interval (CI) in non-Hispanic whites (408 cases and 449 controls). RESULTS: The distribution of genotype frequencies was not different between cases and controls. We observed a significant effect modification between XRCC2 polymorphism and smoking status and pack-year of smoking in modifying pancreatic cancer risk (P value for interaction 0.02 and 0.05, respectively). Compared with never-smokers carrying the XRCC2 Arg188Arg genotype, the OR (95% CI) for individuals carrying the (188)His allele was 2.32 (1.25-4.31) among ever-smokers, 1.43 (0.59-3.48) among light smokers (< or = 22 pack-years), and 3.42 (1.47-7.96) among heavy smokers (> or =22 pack-years). The two XRCC3 SNPs are in strong linkage disequilibrium, but there was no suggestive association between XRCC3 genotype and the risk of pancreatic cancer. CONCLUSION:XRCC2 Arg188His polymorphism may be one of the genetic modifiers for smoking-related pancreatic cancer.
Authors: G Matullo; D Palli; M Peluso; S Guarrera; S Carturan; E Celentano; V Krogh; A Munnia; R Tumino; S Polidoro; A Piazza; P Vineis Journal: Carcinogenesis Date: 2001-09 Impact factor: 4.944
Authors: Bettina Kuschel; Annika Auranen; Simon McBride; Karen L Novik; Antonis Antoniou; Julian M Lipscombe; Nicholas E Day; Douglas F Easton; Bruce A J Ponder; Paul D P Pharoah; Alison Dunning Journal: Hum Mol Genet Date: 2002-06-01 Impact factor: 6.150
Authors: Gregory J Tranah; Edward Giovannucci; Jing Ma; Charles Fuchs; Susan E Hankinson; David J Hunter Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-06 Impact factor: 4.254
Authors: Saeed Rafii; Paul O'Regan; George Xinarianos; Iman Azmy; Tim Stephenson; Malcolm Reed; Mark Meuth; John Thacker; Angela Cox Journal: Hum Mol Genet Date: 2002-06-01 Impact factor: 6.150
Authors: Kevin W O'Connor; Donniphat Dejsuphong; Eunmi Park; Claudia M Nicolae; Alec C Kimmelman; Alan D D'Andrea; George-Lucian Moldovan Journal: Cancer Res Date: 2013-02-22 Impact factor: 12.701
Authors: Rick J Jansen; Sharon Fonseca-Williams; William R Bamlet; Sylvette Ayala-Peña; Ann L Oberg; Gloria M Petersen; Carlos A Torres-Ramos Journal: Mol Carcinog Date: 2014-08-11 Impact factor: 4.784
Authors: Luis Orlando Pérez; Andrea Crivaro; Gisela Barbisan; Lucia Poleri; Carlos Daniel Golijow Journal: Pathol Oncol Res Date: 2013-03-29 Impact factor: 3.201
Authors: Mary E Sehl; Lucy R Langer; Jeanette C Papp; Lorna Kwan; Joyce L Seldon; Geovanni Arellano; Jean Reiss; Elaine F Reed; Sugandha Dandekar; Yael Korin; Janet S Sinsheimer; Zuo-Feng Zhang; Patricia A Ganz Journal: Clin Cancer Res Date: 2009-03-10 Impact factor: 12.531